Mal-Val-Lys-PAB-MMAE (TFA)
Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE TFA consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB) . Mal-Val-Lys-PAB-MMAE TFA can be used for synthesis of ADCs[1].
Product Specifications
UNSPSC
12352005
Target
Drug-Linker Conjugates for ADC; Microtubule/Tubulin
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Field of Research
Cancer
Purity
97.91
Smiles
O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(C=C3)NC([C@H](CCCCN)NC([C@H](C(C)C)NC(CCCCCN4C(C=CC4=O)=O)=O)=O)=O)=O)=O)=O)=O)OC)=O.O=C(O)C(F)(F)F
Molecular Formula
C70H107F3N10O16
Molecular Weight
1401.65
References & Citations
[1]Chen T Z, et al. Novel hydrophilic glycosylation linker, synthesis and application thereof. CN115429889A. 2022-12-06.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
